Results 11 to 20 of about 4,640 (210)

Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy

Frontiers in Oncology
BackgroundSelinexor, a first-in-class, oral exportin-1 inhibitor, showed activity in penta-refractory multiple myeloma (MM) in early trial exploration; however, the side-effect profile of twice-weekly dosing led to hesitant incorporation into widespread ...
Muhamed Baljevic, Gary Schiller, Tomer M. Mark, Dane R. Van Domelen, Cristina Gasparetto   +4 more
doaj   +2 more sources

An evaluation of selinexor’s clinical trial portfolio: a cross-sectional study

Therapeutic Advances in Hematology
Background: Cancer drug development is a complex and costly process. Selinexor is a drug that received accelerated approval as a new treatment for relapsed or refractory diffuse-large B-cell lymphoma and multiple myeloma.
Annes Elfar, Andrew V. Tran, Joseph Case, Cole Wayant, Griffin K. Hughes, Ryan McIntire, Brooke Gardner, Chase Ladd, Andriana M. Peña, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar   +12 more
doaj   +2 more sources

Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial [PDF]

Journal of Immunotherapy and Precision Oncology
Introduction Uveal melanoma remains a disease with aggressive behavior and poor prognosis despite advances in clinical management. Because monotherapy with immune checkpoint inhibitors has led to limited improvement in response rates, combination with ...
Mohamed A. Gouda, Abdulrazzak Zarifa, Yali Yang, Bettzy Stephen, Serdar A. Gurses, Ashabari Sprenger, Yanyan Tian, Mohamed H. Derbala, Isabella Glitza Oliva, Funda Meric-Bernstam, Sapna P. Patel   +10 more
doaj   +2 more sources

Innovative evaluation of selinexor and JQ1 synergy in leukemia therapy via C-MYC inhibition

Journal of Translational Medicine
Background Acute myeloid leukemia (AML) remains a therapeutic challenge due to drug resistance and relapse. Selinexor, an XPO1 inhibitor, shows limited efficacy as monotherapy, necessitating combination strategies. JQ1, a BET inhibitor targeting MYC, may
Pei-Hong Wang, Chu-Hong Hu, Jia-Qi Fan, Jia-Jun He, Ting-Fen Deng, Yan-Li Xu, Yu-Jun Dai, Shun-Qing Wang   +7 more
doaj   +2 more sources

Therapeutic Potential of Exportin 1 and Aurora Kinase A Inhibition in Multiple Myeloma Cells [PDF]

Hematology Reports
Background/Objectives: Aurora kinases (AURKs) are key regulators of mitosis, and their dysregulation contributes to plasma cell disorders, including multiple myeloma (MM) and plasma cell leukemia (PCL). Methods: The expression and prognostic relevance of
Seiichi Okabe, Yuko Tanaka, Shunsuke Otsuki, Mitsuru Moriyama, Seiichiro Yoshizawa, Akihiko Gotoh, Daigo Akahane   +6 more
doaj   +2 more sources

Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study [PDF]

Nature Communications
Exportin-1 (XPO-1) is related to drug resistance and poor prognosis in solid tumors. Selinexor, an XPO-1 inhibitor, has shown preclinical and clinical activity in sarcomas.
Javier Martin-Broto, Antonio Casado, Gloria Marquina, Andres Redondo, Javier Martinez-Trufero, Claudia Valverde, Antonio Gutierrez, Daniel Bernabeu, Luis Ortega, Jose Merino, Rafael Ramos, Patricio Ledesma, Jose L. Mondaza-Hernandez, David S. Moura, Nadia Hindi   +14 more
doaj   +2 more sources

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways. [PDF]

Br J Haematol
Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Kashyap T, Ellero AA, Walker CJ, Maloof ME, Lu M, Xia L, Hoffman R, Taverna P.   +7 more
europepmc   +2 more sources

Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma

Cancer Reports
Background Multiple myeloma (MM) is a blood cancer marked by the abnormal clonal growth of plasma cells. Hypoxia plays a critical role in the progression and treatment resistance of MM. Aims This study investigates the expression of B‐cell/CLL lymphoma 2
Seiichi Okabe, Yuya Arai, Yuko Tanaka, Akihiko Gotoh   +3 more
doaj   +2 more sources

Selinexor—A Drug Review [PDF]

Indian Journal of Medical and Paediatric Oncology, 2021
AbstractSelinexor developed by Karyopharm Therapeutics is the first orally available small-molecule inhibitor of exportin-1 (XPO1). XPO-1 is a protein transporter responsible for the export of macromolecules such as tumor suppressor proteins and oncoprotein mRNAs from the nucleus to the cytoplasm; its inhibition results in blocking of multiple ...
Hridya Jayamohanan, Vaibhav Venniyoor, Keechilat Pavithran   +2 more
openaire   +1 more source

Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E

Frontiers in Oncology, 2021
Selinexor is an FDA approved selective inhibitor of the nuclear export protein exportin-1 (XPO1) and causes specific cancer cell death via nuclear accumulation of tumor suppressor proteins.
Jack G. Fisher, Christopher J. Walker, Amber DP. Doyle, Peter WM. Johnson, Francesco Forconi, Mark S. Cragg, Yosef Landesman, Salim. I. Khakoo, Matthew D. Blunt   +8 more
doaj   +1 more source